Home Newsfeeds Baird Maintains Underperform on Bed Bath & Beyond, Lowers Price Target to $1

Baird Maintains Underperform on Bed Bath & Beyond, Lowers Price Target to $1

Baird analyst Justin Kleber maintains Bed Bath & Beyond (NASDAQ:BBBY) with a Underperform and lowers the price target from $2 to $1.

byBenzinga Newsdesk

January 11, 2023

1 minute read

Baird analyst Justin Kleber maintains Bed Bath & Beyond (NASDAQ:BBBY) with a Underperform and lowers the price target from $2 to $1.

Alzheimer’s Progression Slowed Down By Biogen’s New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

By Shanthi Rexaline

September 28, 12:35 AM

Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.

BIIB

Exelon Q3 Adj EPS $0.75 Beats $0.69 Estimate, Sales $4.84B Miss $5.57B Estimate

By Benzinga Newsdesk

November 3, 6:55 AM

Exelon (NASDAQ:EXC) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.69 by 8.7 percent. The company reported quarterly sales of $4.84 billion which missed the analyst

EXC

Reported Late Tuesday, Arcturus Announces Collaboration With CSL To Develop And Commercialize Self-Amplifying mRNA Vaccines; Arcturus To Receive Upfront Payment Of $200M And More Than $4B In Potential Development And Commercial Milestones

By Benzinga Newsdesk

November 2, 1:17 AM

Arcturus to receive upfront payment of $200 million and more than $4 billion in potential development and commercial milestones 40% profit sharing for COVID-19 vaccines, up to double digit

ARCT

UniFirst Expects FY23 Revenue $2.22B-$2.23B (prior view $2.210B – $2.220B) Vs. $2.22B Estimate; Sees EPS $5.02-$5.37 Vs. $7.13 Estimate

By Benzinga Newsdesk

June 28, 8:12 AM

Financial Outlook The Company now expects its revenues for fiscal 2023 to be between $2.220 billion and $2.230 billion, primarily as a result of the strong top-line performance in the Specialty

UNF

Baird Maintains Underperform on Bed Bath & Beyond, Lowers Price Target to $1

Related Posts

Alzheimer’s Progression Slowed Down By Biogen’s New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

Exelon Q3 Adj EPS $0.75 Beats $0.69 Estimate, Sales $4.84B Miss $5.57B Estimate

Reported Late Tuesday, Arcturus Announces Collaboration With CSL To Develop And Commercialize Self-Amplifying mRNA Vaccines; Arcturus To Receive Upfront Payment Of $200M And More Than $4B In Potential Development And Commercial Milestones

UniFirst Expects FY23 Revenue $2.22B-$2.23B (prior view $2.210B – $2.220B) Vs. $2.22B Estimate; Sees EPS $5.02-$5.37 Vs. $7.13 Estimate